Literature DB >> 25950258

Thrombospondin-2 Expression During Retinal Vascular Development and Neovascularization.

Ping Fei1,2, Tammy L Palenski1, Shoujian Wang1, Zafer Gurel1, Kurt D Hankenson3, Christine M Sorenson4,5, Nader Sheibani1,5,6.   

Abstract

PURPOSE: To determine thrombospondin-2 (TSP2) expression and its impact on postnatal retinal vascular development and retinal neovascularization.
METHODS: The TSP2-deficient (TSP2(-/-)) mice and a line of TSP2 reporter mice were used to assess the expression of TSP2 during postnatal retinal vascular development and neovascularization. The postnatal retinal vascularization was evaluated using immunostaining of wholemount retinas prepared at different postnatal days by collagen IV staining and/or TSP2 promoter driven green fluorescent protein (GFP) expression. The organization of astrocytes was evaluated by glial fibrillary acidic protein (GFAP) staining. Retinal vascular densities were determined using trypsin digestion preparation of wholemount retinas at 3- and 6-weeks of age. Retinal neovascularization was assessed during the oxygen-induced ischemic retinopathy (OIR). Choroidal neovascularization (CNV) was assessed using laser-induced CNV.
RESULTS: Using the TSP2-GFP reporter mice, we observed significant expression of TSP2 mRNA in retinas of postnatal day 5 (P5) mice, which increased by P7 and remained high up to P42. Similar results were observed in retinal wholemount preparations, and western blotting for GFP with the highest level of GFP was observed at P21. In contrast to high level of mRNA at P42, the GFP fluorescence or protein level was dramatically downregulated. The primary retinal vasculature developed at a faster rate in TSP2(-/-) mice compared with TSP2(+/+) mice up to P5. However, the developing retinal vasculature in TSP2(+/+) mice caught up with that of TSP2(-/-) mice after P7. No significant differences in retinal vascular density were observed at 3- or 6-weeks of age. TSP2(-/-) mice also exhibited a similar sensitivity to the hyperoxia-mediated vessel obliteration and similar level of neovascularization during OIR as TSP2(+/+) mice. Lack of TSP2 expression minimally affected laser-induced CNV compared with TSP2(+/+) mice.
CONCLUSIONS: Lack of TSP2 expression was associated with enhanced retinal vascularization during early postnatal days but not at late postnatal times, and minimally affected retinal and CNV. However, the utility of TSP2 as a potential therapeutic target for inhibition of ocular neovascularization awaits further investigation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25950258      PMCID: PMC4575512          DOI: 10.1089/jop.2014.0151

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  36 in total

Review 1.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis.

Authors:  Marcus Fruttiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-02       Impact factor: 4.799

3.  Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity.

Authors:  T R Kyriakides; K J Leach; A S Hoffman; B D Ratner; P Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 4.  Thrombospondin 2, a matricellular protein with diverse functions.

Authors:  P Bornstein; L C Armstrong; K D Hankenson; T R Kyriakides; Z Yang
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

5.  Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens.

Authors:  Zhifeng Wu; Shoujian Wang; Christine M Sorenson; Nader Sheibani
Journal:  Dev Dyn       Date:  2006-07       Impact factor: 3.780

6.  Corneal stromal cells (keratocytes) express thrombospondins 2 and 3 in wound repair phenotype.

Authors:  David J Armstrong; Paul Hiscott; Mark Batterbury; Stephen Kaye
Journal:  Int J Biochem Cell Biol       Date:  2002-06       Impact factor: 5.085

7.  Expression of thrombospondin-1 in ischemia-induced retinal neovascularization.

Authors:  K Suzuma; H Takagi; A Otani; H Oh; Y Honda
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

8.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

9.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

10.  Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes.

Authors:  Shoujian Wang; Justin L Gottlieb; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2009-04
View more
  4 in total

Review 1.  Negative regulators of angiogenesis: important targets for treatment of exudative AMD.

Authors:  Mitra Farnoodian; Shoujian Wang; Joel Dietz; Robert W Nickells; Christine M Sorenson; Nader Sheibani
Journal:  Clin Sci (Lond)       Date:  2017-07-05       Impact factor: 6.124

Review 2.  Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD.

Authors:  Mitra Farnoodian; Christine M Sorenson; Nader Sheibani
Journal:  J Ophthalmic Vis Res       Date:  2018 Oct-Dec

3.  Targeted Thrombospondin-1 Expression in Ocular Vascular Development and Neovascularization.

Authors:  Christine M Sorenson; Shoujian Wang; Soesiawati R Darjatmoko; Zafer Gurel; Bo Liu; Nader Sheibani
Journal:  Front Cell Dev Biol       Date:  2021-04-21

4.  Thrombospondin-2 spatiotemporal expression in skeletal fractures.

Authors:  Robert L Zondervan; Daniel C Jenkins; John D Reicha; Kurt D Hankenson
Journal:  J Orthop Res       Date:  2020-05-28       Impact factor: 3.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.